Skip to content
Bio Alps
FIND A HEALTH VALLEY ACTOR
Menu
Search
News
BioAlps news
BioAlps 20 years
Events
About
Mission
Organization
Members and Strategic Partners
BioAlps Awards
Media Center
BioAlps Event Formats
Business
Opportunities
Community
Membership Registration
The BioAlps Community
Cluster Expertise
Big data and bioinformatics
Biomaterials
Bioservices
Cardiovascular
Diagnostics
Drug delivery devices and development
Endocrinology and metabolism
Immunology
Medical technology
Neuroscience
Oncology
Orphan Drugs
The Health Valley
Business Enablers
Industrial network
Economic Promotion
International Markets
Innovation Enablers
Industrial Networks and Support Institutions
Technology Transfer Organisations
Incubators and Technoparks
Coaching
Financing
Startups and Success Stories
Research Institutions and Education
Universities and Academic Institutions
Research Centres
Research Networks
Education and Training
COVID-19 Key Players
News
« Back to News Listing
Posts navigation
← Retraites Populaires and Biopôle SA launch the first life sciences incubator in Canton of Vaud
Swiss BioInformatics Institute celebrates its 20th anniversary →
EspeRare gains rights to relaunch late stage development for a rare genetic disease
26.04.2018
Share this article
Facebook
X (Twitter)
Linkedin
EspeRare is delighted to announce that it has concluded an important agreement with Edimer Pharmaceuticals.
Lire le communiqué de presse
Read the press release
Latest articles
10.02.2026
DSM-Firmenich divests its Animal Nutrition and Health business
10.02.2026
Swissmedic approves donanemab for the treatment of early-stage Alzheimer’s disease
09.02.2026
Noa Schmid gets the CSEM Inventor Award 2026
05.02.2026
George Coukos appointed director of new Ludwig Laboratory for Cell Therapy in New York
05.02.2026
Swiss Biotech HemostOD Secures CHF 2 Million Innosuisse Grant to Advance Universal Platelet Technology
